SERPINE1 and melanoma: Next, to determine whether baseline serum levels of PAI-1 might be associated with early response in melanoma patients treated with anti-PD1 Abs, PAI-1 levels were evaluated in 49 patients (cohort 2) with advanced melanoma treated with anti-PD1 Abs.